Key result
Adding degradable starch microspheres cuts urinary doxorubicin excretion by ~29% in rats.
Answers are grounded in this paper and cite their sources.
Starch microspheres may reduce systemic doxorubicin exposure in hepatic IA rat models; leaves open translation to human therapeutic index.
Urinary concentration of doxorubicin and its active metabolite doxorubicinol was followed in two groups of rats after hepatic intra-arterial injection of a single dose of 6 mg/kg doxorubicin or the same dose combined with 30 mg/kg Spherex (DSM). Urinary samples were collected during five days following administration. The concomitant DSM administration caused a significant decrease of the cumulative urinary excretion of intact doxorubicin; average five days of cumulative values were 73 and 103 micrograms respectively in the group with and without DSM. This indicates a DSM-induced reduction in systemic drug exposure. The elimination rates of doxorubicin or its active metabolite were not influenced by DSM. The decrease in excretion of the parent drug was not due to an interaction between the drug and DSM as evident by examining the binding of doxorubicin to DSM in vitro. Instead regionally altered drug distribution seems a plausible explanation to the reduction.
No takes yet. Share an insight, caveat, or question.
Johansson et al. (1994) studied this question. Doxorubicin and Spherex (DSM) vs. 6 mg/kg doxorubicin alone was evaluated on Cumulative urinary excretion of intact doxorubicin over 5 days. Concomitant administration of degradable starch microspheres with doxorubicin significantly decreased the 5-day cumulative urinary excretion of intact doxorubicin (73 vs 103 micrograms) in rats.
Synapse has enriched 10 related papers. Consider them for comparative context: